Global Palmoplantar Pustulosis Treatment Market - 2023-2030

Overview

Palmoplantar psoriasis is a type of psoriasis on the hands and feet. It causes patches of scaly, flaky, discolored skin. Symptoms can affect the skin on the top and bottom of the hands and feet, as well as on and in between the fingers and toes. Palmoplantar pustulosis is an auto-inflammatory skin disease but the exact cause of the condition is still not fully understood. It sometimes runs in families and rarely occurs before adulthood. Smokers seem to be especially prone to this type of psoriasis.

Moreover, there isn't a cure for psoriasis, but treatment is available to help manage the symptoms. Medications such as topical steroids are applied directly to reduce the blisters, emollients such as salicylic acid ointment and urea cream are most commonly used to moisturize the skin, retinoid medications, and phototherapy are also used, and in severe cases, immunosuppressants like methotrexate or cyclosporine are commonly used. If these medications are not tolerated or are inefficient, biologicals like TNF-alpha blockers such as etanercept and adalimumab, anti-IL-12/23 inhibitors such as ustekinumab, anti-IL-23 inhibitors mainly guselkumab and anti-IL-17 are prescribed.

Market Dynamics: Drivers

Increasing demand for novel and advanced therapeutics

The increasing demand for novel and advanced therapeutics is expected to drive the market over the forecast period. The novel therapeutics aim to address the unmet needs associated with the management of symptoms of palmoplantar pustulosis by providing alternative or complementary treatment options for better disease management. Many pharmaceutical companies are focusing on the development of novel therapeutics with advanced outcomes.

For instance, on August 23, 2023, Kyowa Kirin Co., Ltd. Released that the company has received approval from the Ministry of Health, Labour and Welfare (MHLW) for partial change of approved indication of LUMICEF (brodalumab) for the treatment of palmoplantar pustulosis that respond inadequately to existing therapies.

LUMICEF is a fully human anti-interleukin-17 (IL-17) receptor A antibody that inhibits the biological activity of inflammatory cytokines such as IL-17A, IL-17A/F, IL-17F and IL-17C by binding to IL-17A receptor selectively. LUMICEF is the first IL-17 pathway inhibitor approved for palmoplantar pustulosis.

In Addition, regulatory approvals such as FDA approvals increase the trust in patients about the development of novel advanced therapeutics. For instance, on December 15, 2021, Boehringer Ingelheim cleared that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for spesolimab for the treatment of generalized pustular psoriasis flares.

Further, the increasing prevalence of palmoplantar pustulosis, rising FDA approvals for innovative drugs, increasing clinical trials, increasing awareness and advancements in the development of novel therapies and technological advancements in phototherapy are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and side effects associated with topical steroids and other drugs, the high cost of the phototherapy treatment, risks associated with phototherapy and lack of better and quick treatment are expected to hamper the market.

Segment Analysis

The global palmoplantar pustulosis treatment market is segmented based on treatment type, route of administration, sales channel and region.

The topical steroids segment accounted for approximately 52.4% of the palmoplantar pustulosis treatment market share

The topical steroids segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for this disease, but topical steroids are considered first-line therapeutics for the management of palmoplantar pustulosis. These medications, also known as topical corticosteroids, are applied directly to the affected skin to help reduce inflammation and alleviate symptoms such as redness, itching, and the formation of pustules.

Moreover, topical steroids work by suppressing the immune response and reducing inflammation. In palmoplantar pustulosis, where inflammation plays a significant role in the development of pustules, these medications can help manage symptoms and severity. Topical steroids come in varying strengths, and the choice of strength depends on the severity of the condition and the affected areas. Short-term use of high-potency steroids may be necessary for acute flare-ups, while lower-potency options are often used for maintenance therapy.

Further, their wide availability, acceptability, and, ease of application helps to hold the largest market share. In some cases, topical steroids may be used in combination with other topical agents or systemic medications to enhance therapeutic effects and manage the condition comprehensively. In addition, their wide adoption also increases the demand for the topical steroids.

Geographical Analysis

North America accounted for approximately 41.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing R&D activities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in clinical trials, leads to the launch of novel therapeutics and alternative treatment options for better patient outcomes.

For instance, on March 08, 2021, AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, released that top-line data from its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe palmoplantar pustulosis (PPP).

Furthermore, the region has a strong presence of pharmaceutical companies engaged in research and development. New and innovative treatments may be more readily available in North America. As the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics, which results in better patient outcomes.

Competitive Landscape

The major global players in the palmoplantar pustulosis treatment market include: F. Hoffmann-La Roche Ltd, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Kyowa Kirin Co., Ltd., Novartis AG, Amgen Inc., Janssen Biotech, Inc., AdvaCare Pharma, Palsons Derma Pvt Ltd and SiNi Pharma Pvt Ltd. Among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global palmoplantar pustulosis treatment market. The pandemic created unprecedented challenges for pharmaceutical industries worldwide, including the global palmoplantar pustulosis treatment market by temporarily disrupting many clinical trials and research activities due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these treatment medications globally.

Market Segmentation

By Treatment Type

• Topical Steroids or Calcipotriene Creams
• Emollients
  • Salicylic Acid Ointment
  • Urea Cream
  • Heel Balm
  • Others
• Retinoid Medications
  • Acitretin
  • Retinol
  • Bexarotene
  • Alitretinoin
  • Others
• Immunosuppressants
  • Methotrexate
  • Cyclosporine
  • Others
• Biologics
  • TNF-Alpha Blockers
• Etanercept
• Adalimumab
• Others
  • Anti Interleukin Inhibitors
• Ustekinumab
• Guselkumab
• Others
• Tetracycline Antibiotics
• Phototherapy
  • Narrowband UVB
  • Photochemotherapy
  • PUVA
• Others

By Route Of Administration

• Oral
• Topical
• Intravenous
• Others

By Sales Channel

• Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• End-User
  • Hospitals
  • Dermatology Clinics
  • Phototherapy Centers
  • Academic and Research Institutes
  • Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report?

• To visualize the global palmoplantar pustulosis treatment market segmentation based on treatment type, route of administration, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of palmoplantar pustulosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global palmoplantar pustulosis treatment market report would provide approximately 61 tables, 61 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies